- Home
- PRQR vs RCEL Comparison
PRQR vs RCEL Comparison
Compare PRQR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- RCEL
- Stock Information
- Founded
- PRQR 2012
- RCEL N/A
- Country
- PRQR Netherlands
- RCEL United States
- Employees
- PRQR N/A
- RCEL N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- PRQR Health Care
- RCEL Health Care
- Exchange
- PRQR Nasdaq
- RCEL Nasdaq
- Market Cap
- PRQR 179.1M
- RCEL 170.8M
- IPO Year
- PRQR 2014
- RCEL N/A
- Fundamental
- Price
- PRQR $1.94
- RCEL $5.80
- Analyst Decision
- PRQR Strong Buy
- RCEL Strong Buy
- Analyst Count
- PRQR 7
- RCEL 4
- Target Price
- PRQR $9.00
- RCEL $16.50
- AVG Volume (30 Days)
- PRQR 302.0K
- RCEL 287.3K
- Earning Date
- PRQR 08-07-2025
- RCEL 08-07-2025
- Dividend Yield
- PRQR N/A
- RCEL N/A
- EPS Growth
- PRQR N/A
- RCEL N/A
- EPS
- PRQR N/A
- RCEL N/A
- Revenue
- PRQR $21,212,711.00
- RCEL $71,661,000.00
- Revenue This Year
- PRQR $2.87
- RCEL $57.29
- Revenue Next Year
- PRQR N/A
- RCEL $28.07
- P/E Ratio
- PRQR N/A
- RCEL N/A
- Revenue Growth
- PRQR 85.91
- RCEL 41.35
- 52 Week Low
- PRQR $1.07
- RCEL $5.46
- 52 Week High
- PRQR $4.62
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- PRQR 63.06
- RCEL 35.27
- Support Level
- PRQR $1.77
- RCEL $5.87
- Resistance Level
- PRQR $1.96
- RCEL $6.33
- Average True Range (ATR)
- PRQR 0.10
- RCEL 0.38
- MACD
- PRQR 0.01
- RCEL 0.09
- Stochastic Oscillator
- PRQR 80.78
- RCEL 30.09
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.